Social Capital Suvretta Holdings Corp. III
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNAC research report →
Price Chart
About the company
Social Capital Suvretta Holdings Corp. III presently conducts no significant commercial activities. Its core objective is to finalize a business combination, which may involve a merger, capital stock exchange, asset acquisition, stock purchase, or corporate reorganization, with one or more other entities.
- CEO
- Chamath Palihapitiya
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on DNAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.16B
- P/E
- -1.73
- PEG
- 0.18
- P/S
- 451.23
- P/B
- -0.24
- EV/EBITDA
- -1.54
- Div Yield
- 0.00%
- Gross Margin
- -12872.90%
- Op Margin
- -24830.32%
- Net Margin
- -13326.71%
- ROE
- 10.80%
- ROIC
- -104.32%
Latest fiscal year · YoY change
- Revenue
- $893.00K+1075.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-165,007,000
- Net Income
- $-82,626,000+19.1%
- EPS
- $0.00+0.0%
- OCF Growth
- +4.9%
- FCF Growth
- +4.9%
- Beta
- 0.00
- RSI (14)
- 43
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ProKidney said Phase II REACT data continued to show kidney-function preservation, but it is narrowing Phase III enrollment to higher-risk patients and delaying both manufacturing and trial timelines into 2024.· November 14, 2023
- Phase II RMCL-002 update showed REACT was well tolerated, with no significant REACT-related serious adverse events and procedure-related events in 6 of 83 treated patients.
- In the active group, average eGFR declined by minus 3.2 mL over 30 months, while the deferred group fell by minus 3.4 mL over 12 months on standard of care.
- After crossover to REACT, the deferred group’s average eGFR decline slowed to only 0.2 mL over the next 18 months, with the strongest signal in stage 4 CKD and severe albuminuria.
- Proact 1 will be enriched to eGFR 20-35 mL/min and will add 600 incremental patients; proact 2 is unchanged at eGFR 20-44 and UACR >300.
- Enrollment in proact 1 and manufacturing are both expected to resume in the first half of 2024 after protocol and EU quality-system changes.
ProKidney did not report revenue or EPS on this call. In Phase II RMCL-002, the company said 43% of enrolled subjects had stage 4 CKD; baseline eGFR was 33.9 and 31.8 mL/min in the active and deferred arms, respectively; and baseline UACR was 740 and 598 mg/g. In the active arm, average eGFR changed by minus 3.2 mL over 30 months; the deferred arm declined by minus 3.4 mL over 12 months on standard of care; and after REACT crossover, the deferred arm’s average eGFR decline was 0.2 mL over the next 18 months. Among 73 injected patients, 27 patients (37%) had no or minimal decline in kidney function over 30 months, and the stage 4/severe albuminuria subgroup (13 patients per arm) showed minus 1.6 mL change in the active group versus minus 6 mL on standard of care. Guidance-wise, ProKidney expects final RMCL-002 safety and efficacy results in the first half of 2024, interim 007 results around mid-2024, final 007 results in the first half of 2025, proact 1 enrollment to resume in the first half of 2024, proact 2 to commence enrollment in the first half of 2024, and both Phase III studies to complete in 2027.
Dr. Bruce Culleton framed the Phase II readout as supportive of REACT’s potential to preserve kidney function, especially in the highest-risk CKD patients with stage 4 disease and severe albuminuria. He said the company is intentionally narrowing proact 1 to eGFR 20-35 to better match the data and improve the probability of success, while leaving proact 2 unchanged. His tone was more confident by the end of the call, saying he came in with “optimistic skepticism” but is now “definitely more optimistic” after reviewing the data.
The CFO did not provide a separate detailed financial review on the call, and no revenue, EPS, cash balance, or margin figures were reported. Management did say the company is “well capitalized well into 2025,” and Bruce Culleton referenced “a couple of potential financing catalysts” in the interim. On capital allocation, the focus was on preserving resources while pausing manufacturing and Phase III enrollment to address the EU qualified person audit and protocol changes.
Analysts focused on why proact 1 would be delayed if 20-35 eGFR patients were already enrolling, what happens to patients already enrolled above the new cutoff, whether FDA discussions had occurred, and whether interim analysis timing would change. Management said patients already enrolled outside the new criteria will continue under protocol and be included in the final FDA analysis set, and that the protocol changes and manufacturing pause are the reasons for the delay. On FDA, management said the change is not viewed internally as a significant modification and should be handled with a notification letter rather than a formal meeting; they also said interim analysis timing is still under review. Questions also addressed durability/redosing, GLP-1 competition, and why proact 2 was not narrowed further; management said durability is still uncertain, redosing may be needed after 18-24 months, GLP-1 data are still evolving, and proact 2 remains broader to preserve labeling and addressable-market optionality.
The company’s best-case argument from this call is that REACT showed stabilization of kidney function rather than just slowing decline, particularly in stage 4 CKD patients with severe albuminuria. Management also argued the focused trial design should improve enrollment quality, speed event accumulation, and better align the Phase III program with the strongest observed signal.
The main risks are the new delays: proact 1 enrollment is being pushed back, manufacturing is paused, and management has not yet committed to a new interim-analysis timeline. The durability of effect is still uncertain, management acknowledged possible redosing may be needed, and the company must also resolve EU quality-system deficiencies before resuming manufacturing and clinical supply.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 15.1%
- Shares Outstanding
- 232.75M
- Float Shares
- 35.04M
of shares held by institutions
80 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 24, 21 | Sinha Uma | other | 0 |
| Aug 16, 21 | SCS Sponsor III LLC | sell | 75,000 |
| Jul 2, 21 | SCS Sponsor III LLC | other | 640,000 |
| Jun 29, 21 | SCS Sponsor III LLC | other | 0 |
| Jun 29, 21 | Semigran Marc | other | 0 |
| Jun 29, 21 | Ryans James | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DNAC coverage
Recent articles, reports, and earnings notes.
No research on DNAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNAC report →ProKidney to present at upcoming investor conferences
globenewswire.com · May 20
ProKidney to Present REACT® at 4th Annual CKD Summit
globenewswire.com · Mar 1
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
pulse2.com · Jan 18
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
benzinga.com · Jan 18
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
marketwatch.com · Jan 18
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
benzinga.com · Jan 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.